Site Wide Notice

Coronavirus Update - 24th March 2020

We understand our customers concerns relating to the spread of COVID-19 and would like to assure you that we are located in one of the least affected areas of the UK and are open for business as usual.

Click here for latest information

Arcinova Releases Latest Case Study

The challenge - to develop stable sterile formulations of a drug substance for intravenous administration in phase I clinical trials.  The drug substance, intended for the treatment of CNS (Central Nervous System) related disorders, was physically and chemically unstable in aqueous media and there was a requirement for the product to be delivered both as a bolus and maintenance dose over an extended period of several days.

Find out more about how we solved the issue here